Skip to main content
Peptyds
Research notes

CJC-1295 vs Ipamorelin: How a GHRH Analogue and a Selective GHRP Differ

CJC-1295 is a long-acting GHRH analogue studied for its ability to extend the half-life of growth-hormone-releasing-hormone signalling — the DAC-modified version reports a multi-day plasma life in early pharmacokinetic literature. Ipamorelin is a selective pentapeptide GHRP-6 derivative that acts on the ghrelin/GHS receptor and is described as releasing growth hormone with low effect on cortisol or prolactin in preclinical work. They are often paired in animal-model research because GHRH and GHRP arms of the axis act through different receptors and have shown synergistic GH release in early human studies. Neither molecule is authorised as a medicine by the EMA, and any clinical use of growth-hormone therapy in Europe goes through approved recombinant-GH pathways prescribed by a specialist.

10 min readUpdated 13 May 2026Reviewed by Independent EU laboratory (ISO/IEC 17025)
Two unlabeled lyophilised peptide vials at slightly different angles on a navy lab surface, suggesting paired GHRH and GHRP research peptides.
Two unlabeled lyophilised peptide vials at slightly different angles on a navy lab surface, suggesting paired GHRH and GHRP research peptides.
Jump to section
  1. 01Two molecules, two arms of the same axis
  2. 02GHRH amplitude versus GHRP pulse: the mechanism story
  3. 03Side-by-side: what the research actually compares
  4. 04Why animal studies pair them — and what that does not prove
  5. 05EMA status: neither is an authorised medicine
  6. 06How a careful buyer reads a 'CJC ipamorelin' page
  • CJC-1295 is a long-acting GHRH analogue; ipamorelin is a selective GHRP/GHS-receptor agonist.
  • GHRH (CJC-1295) controls the amplitude of growth-hormone pulses while GHRP (ipamorelin) restores the pulse itself — the popular 'pulse plus amplitude' framing.
  • DAC-modified CJC-1295 has an extended half-life of approximately 5-8 days; ipamorelin acts on a far shorter time scale.
  • Animal studies often pair them because the GHRH and GHRP receptors are structurally distinct and the early-human literature suggests synergistic GH release.
  • Neither is EMA-authorised as a medicine; recombinant human growth hormone is the only EMA-approved GH replacement therapy.
  • This is research-context education, not a dosing protocol or treatment recommendation.

Two molecules, two arms of the same axis

CJC-1295 and ipamorelin sit on opposite sides of the growth-hormone-releasing axis. CJC-1295 is a 30-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH), studied in early pharmacokinetic literature as a long-acting form that engages the GHRH receptor on the anterior pituitary. The DAC (drug-affinity-complex) version is engineered to bind albumin, extending plasma life to approximately 5-8 days in normal adults.[1]

Ipamorelin is a pentapeptide growth-hormone-releasing-peptide (GHRP) derivative of GHRP-6, introduced as the first selective GH secretagogue in preclinical work. It binds the ghrelin/growth-hormone-secretagogue receptor (GHS-R) and releases GH with little reported effect on cortisol or prolactin in the foundational discovery paper.[2]

The same axis, two distinct receptors. That structural fact is what every honest CJC-1295 vs ipamorelin discussion has to start from — not 'which is stronger', but 'what does each one actually trigger'.[3]

GHRH amplitude versus GHRP pulse: the mechanism story

In endocrinology research, GHRH and GHRP arms are described as complementary. GHRH controls the amplitude of growth-hormone pulses — how big each release is. GHRP (and the ghrelin pathway it mimics) acts on a different receptor to initiate or restore the pulse itself, and is hypothesised to also suppress somatostatin tone.[3]

The 'pulse plus amplitude' framing that fitness forums popularised has its scientific origin in studies that administered a GHRH analogue and a GHRP together and observed greater GH release than either alone in healthy subjects. That synergy is the published reason animal-model research has paired these classes.[3][4]

It is worth being precise: 'synergy in an acute GH-release assay' is not the same as 'this combination is a validated long-term therapy'. The literature describes the pharmacology, not a clinical protocol.[3]

Side-by-side: what the research actually compares

The table below summarises what published preclinical and early-human literature tends to discuss for each peptide. Treat it as a research-context map, not a clinical recommendation.[1][2][3]

| Attribute | CJC-1295 (DAC) | Ipamorelin | | --- | --- | --- | | Class | Long-acting GHRH analogue (30 amino acids) | Selective GHRP / GHS-R agonist (pentapeptide) | | Receptor | GHRH receptor on anterior pituitary | Ghrelin / growth-hormone-secretagogue receptor (GHS-R) | | Reported plasma half-life | ~5-8 days (DAC version) in normal adults | Short — order of hours in early discovery work | | Primary effect described in literature | Increases amplitude of GH pulses | Initiates / restores a GH pulse with low cortisol or prolactin effect | | Typical research framing | Sustained GHRH-receptor activation | Selective GH secretagogue with clean preclinical profile | | Human clinical evidence | Limited; early pharmacokinetic and proof-of-mechanism studies | Limited; foundational discovery work plus small clinical trials | | EMA status | Not authorised as a medicine | Not authorised as a medicine | | Common buyer question | 'How long does it last?' | 'Does it spike cortisol?' | | Honest answer | The pharmacokinetic data is real; the long-term human safety dataset is not. | The selectivity profile is real in early work; the long-term human safety dataset is not. |[1][2][3][5]

Read the table as a way to compare research stories. It does not predict what either peptide will do for any specific person, and it should not be reinterpreted as a dosing chart.

Why animal studies pair them — and what that does not prove

Pairing a GHRH analogue with a GHRP is a long-standing design in growth-hormone research, because the two arms of the axis are structurally independent. Activating both produces a different GH response than activating either one alone, and that effect has been described in healthy adults in published combination studies.[3][4]

Online, that observation often turns into 'CJC-1295 ipamorelin stack' content with weekly dose protocols, cycle lengths, and outcome promises. The literature does not validate any of that as a clinical regimen. There are no large, long-duration randomised human trials comparing such a stack to placebo for body-composition or longevity endpoints.[3][7]

The honest reading is that the synergy is real as an acute pharmacology observation, and the consumer 'stack' is an extrapolation that runs ahead of the published data.[3]

EMA status: neither is an authorised medicine

Recombinant human growth hormone (somatropin) is the EMA-authorised route for diagnosed adult and paediatric growth-hormone deficiency. The EMA's guidance on clinical investigation of recombinant human growth hormone is the regulatory frame for that category, and it is prescribed by specialists after diagnostic workup.[5][6]

Neither CJC-1295 nor ipamorelin has an EMA EPAR as a marketed medicine. Their use sits in laboratory and research-peptide context, not in the consumer-medicine pathway. That is not a gap in this article — it is the most important regulatory fact a buyer should hold before reading any 'stack' content.[5][6]

How a careful buyer reads a 'CJC ipamorelin' page

When two molecules both sit in research-stage territory, the honest comparison is not 'which works better' but 'which research literature, regulatory framing, and quality system fits the buyer's standards'.[7]

Practical checks: batch-specific Certificate of Analysis, HPLC purity context with method, identity confirmation, ISO/IEC 17025 lab signal, cold-chain shipping practice, and content language that distinguishes preclinical pharmacology from human clinical outcomes.

Continue reading:View CJC-1295 No-DACView IpamorelinExplore muscle and sleep goal

Sources

  1. [01]
  2. [02]
  3. [03]
  4. [04]
  5. [05]
  6. [06]
    European Medicines Agency
    Clinical trials in human medicines
  7. [07]

Questions

Is ipamorelin stronger than CJC-1295?

'Stronger' is the wrong frame. CJC-1295 and ipamorelin act on different receptors. GHRH analogues like CJC-1295 increase the amplitude of GH pulses; selective GHRPs like ipamorelin initiate or restore a pulse. The published literature describes them as complementary, not as rivals.[3][2]

How long does CJC-1295 last?

The DAC-modified form of CJC-1295 has been reported in early pharmacokinetic literature with a plasma half-life of approximately 5-8 days in normal adults — the design intention behind albumin binding. The non-DAC form is much shorter-acting.[1]

Why are CJC-1295 and ipamorelin often paired in research?

Because the GHRH receptor and the GHS-R (ghrelin) receptor are structurally distinct, and combined activation in healthy human studies has shown greater acute GH release than either alone. That is the 'pulse plus amplitude' framing. It describes acute pharmacology, not a validated long-term therapy.[3][4]

Are CJC-1295 or ipamorelin approved medicines in the EU?

No. Neither molecule has an EMA EPAR as a marketed medicine. Recombinant human growth hormone is the EMA-authorised route for diagnosed growth-hormone deficiency, prescribed by specialists.[5][6]

Is the 'CJC ipamorelin stack' a clinical protocol?

No. The combination has acute pharmacology data in healthy subjects, but no large, long-duration randomised human trial has validated the consumer 'stack' for body-composition, longevity, or other outcome endpoints. Any decision about GH-axis therapy belongs with a qualified healthcare professional.[3][7]

Educational content. Not medical advice.

Next step

Choose the route that matches how you read.

Shop by goalShop all peptidesRead quality protocolView CJC-1295 No-DAC